MX369156B - Formulaciones de adenovirus mejoradas. - Google Patents

Formulaciones de adenovirus mejoradas.

Info

Publication number
MX369156B
MX369156B MX2016003414A MX2016003414A MX369156B MX 369156 B MX369156 B MX 369156B MX 2016003414 A MX2016003414 A MX 2016003414A MX 2016003414 A MX2016003414 A MX 2016003414A MX 369156 B MX369156 B MX 369156B
Authority
MX
Mexico
Prior art keywords
formulations
adenovirus formulations
improved adenovirus
improved
adenoviruses
Prior art date
Application number
MX2016003414A
Other languages
English (en)
Other versions
MX2016003414A (es
Inventor
Adriaansen Janik
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX369156(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MX2016003414A publication Critical patent/MX2016003414A/es
Publication of MX369156B publication Critical patent/MX369156B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a formulaciones farmacéuticas de adenovirus, en particular formulaciones farmacéuticas líquidas que comprenden adenovirus.
MX2016003414A 2013-09-19 2014-09-16 Formulaciones de adenovirus mejoradas. MX369156B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13185200 2013-09-19
PCT/EP2014/069654 WO2015040002A1 (en) 2013-09-19 2014-09-16 Improved adenovirus formulations

Publications (2)

Publication Number Publication Date
MX2016003414A MX2016003414A (es) 2016-06-30
MX369156B true MX369156B (es) 2019-10-30

Family

ID=49212683

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003414A MX369156B (es) 2013-09-19 2014-09-16 Formulaciones de adenovirus mejoradas.

Country Status (32)

Country Link
US (3) US9974737B2 (es)
EP (1) EP3046536B1 (es)
JP (1) JP6013654B2 (es)
KR (1) KR102258348B1 (es)
CN (2) CN105530917B (es)
AP (1) AP2016009154A0 (es)
AU (1) AU2014323230B2 (es)
BR (1) BR112016005761B1 (es)
CA (1) CA2923352C (es)
CL (1) CL2016000621A1 (es)
CY (1) CY1122796T1 (es)
DK (1) DK3046536T3 (es)
EA (1) EA036046B1 (es)
ES (1) ES2711115T3 (es)
HR (1) HRP20182159T1 (es)
HU (1) HUE041791T2 (es)
IL (1) IL244572A (es)
LT (1) LT3046536T (es)
ME (1) ME03324B (es)
MX (1) MX369156B (es)
MY (1) MY181190A (es)
NZ (1) NZ717156A (es)
PE (1) PE20160527A1 (es)
PH (1) PH12016500316A1 (es)
PL (1) PL3046536T3 (es)
PT (1) PT3046536T (es)
RS (1) RS58393B1 (es)
SG (1) SG11201601181SA (es)
SI (1) SI3046536T1 (es)
TR (1) TR201900274T4 (es)
WO (1) WO2015040002A1 (es)
ZA (1) ZA201601919B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2988780T3 (pl) 2013-04-25 2019-06-28 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
EP3561062A1 (en) 2013-09-13 2019-10-30 California Institute of Technology Selective recovery
CA2923352C (en) 2013-09-19 2022-05-03 Crucell Holland B.V. Stable adenovirus formulations
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
KR102638978B1 (ko) 2015-07-07 2024-02-22 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
CA3001050C (en) * 2015-10-06 2023-03-28 Janssen Vaccines & Prevention B.V. Method for preventing surface-induced degradation of viruses using cyclodextrins
WO2017100671A1 (en) 2015-12-11 2017-06-15 California Institute Of Technology TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
KR102506895B1 (ko) 2016-04-05 2023-03-08 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 용해성 융합-전 rsv f 단백질
CA3018139A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
KR102421049B1 (ko) 2016-05-30 2022-07-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합-전 rsv f 단백질
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
KR20200053518A (ko) 2017-09-15 2020-05-18 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 면역의 안전한 유도를 위한 방법
WO2020068990A1 (en) 2018-09-26 2020-04-02 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
EP3908264A1 (en) * 2019-01-09 2021-11-17 Ziccum AB Stabilized non-enveloped virus compositions
WO2023282796A2 (en) * 2021-07-08 2023-01-12 Limited Liability Company «ANABION» Pharmaceutical composition of non-enveloped virus
WO2023240196A1 (en) * 2022-06-08 2023-12-14 Gritstone Bio, Inc. Compositions and methods of use thereof
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations
WO2024079657A1 (en) * 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Formulations for aav gene therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP1977764A1 (en) * 1998-11-16 2008-10-08 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
CA2399321C (en) * 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
EP1453536A4 (en) * 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
JP4727923B2 (ja) * 2001-12-20 2011-07-20 シェーリング コーポレイション Ｓｙｎ３組成物およびその方法
US20030180936A1 (en) * 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
ATE447037T1 (de) 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
NZ539813A (en) 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
US7355056B2 (en) * 2003-06-04 2008-04-08 Canji, Inc. Transfection agents
MXPA05013983A (es) * 2003-06-30 2006-03-02 Canji Inc Encapsulacion polimerica de adenovirus.
WO2005052116A2 (en) * 2003-11-19 2005-06-09 Merck & Co., Inc. Preservative-containing virus formulations
EP1726640B1 (en) * 2004-03-04 2016-01-13 Sumitomo Dainippon Pharma Co., Ltd. Rat embryonic stem cell
SG159555A1 (en) 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
CN1883707A (zh) * 2006-05-19 2006-12-27 吉林大学 重组腺病毒的冻干制剂及其制备方法
GB0715723D0 (en) * 2007-08-11 2007-09-19 Ark Therapeutics Ltd Formulation
WO2011028962A1 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody coformulations
GB201002419D0 (en) 2010-02-12 2010-03-31 Isis Innovation Stable live vaccine formulations
WO2012110971A2 (en) 2011-02-17 2012-08-23 Promed Exports Pvt. Ltd. Method and composition to retard sorption of preservatives to plastics
CA2923352C (en) * 2013-09-19 2022-05-03 Crucell Holland B.V. Stable adenovirus formulations
CN104027815A (zh) 2014-06-12 2014-09-10 中国农业科学院兰州畜牧与兽药研究所 一种丹参酮包合液及其制备方法和应用
CA3001050C (en) 2015-10-06 2023-03-28 Janssen Vaccines & Prevention B.V. Method for preventing surface-induced degradation of viruses using cyclodextrins

Also Published As

Publication number Publication date
CY1122796T1 (el) 2021-05-05
US11484494B2 (en) 2022-11-01
HUE041791T2 (hu) 2019-05-28
EA201690613A1 (ru) 2016-08-31
CA2923352C (en) 2022-05-03
KR20160055180A (ko) 2016-05-17
US9974737B2 (en) 2018-05-22
ME03324B (me) 2019-10-20
KR102258348B1 (ko) 2021-05-31
LT3046536T (lt) 2019-03-12
ES2711115T3 (es) 2019-04-30
US10272032B2 (en) 2019-04-30
SI3046536T1 (sl) 2019-05-31
NZ717156A (en) 2022-04-29
US20180235871A1 (en) 2018-08-23
ZA201601919B (en) 2017-06-28
TR201900274T4 (tr) 2019-02-21
BR112016005761A2 (es) 2017-08-01
CN105530917A (zh) 2016-04-27
AP2016009154A0 (en) 2016-04-30
BR112016005761B1 (pt) 2022-09-20
CA2923352A1 (en) 2015-03-26
IL244572A (en) 2017-02-28
DK3046536T3 (en) 2019-03-11
AU2014323230B2 (en) 2017-05-25
EA036046B1 (ru) 2020-09-18
US20190240146A1 (en) 2019-08-08
WO2015040002A1 (en) 2015-03-26
MY181190A (en) 2020-12-21
JP6013654B2 (ja) 2016-10-25
CN111514314A (zh) 2020-08-11
CL2016000621A1 (es) 2016-11-25
PT3046536T (pt) 2019-02-25
PH12016500316B1 (en) 2016-05-02
CN105530917B (zh) 2020-06-05
IL244572A0 (en) 2016-04-21
PH12016500316A1 (en) 2016-05-02
AU2014323230A1 (en) 2016-03-17
EP3046536B1 (en) 2018-11-28
HRP20182159T1 (hr) 2019-02-22
RS58393B1 (sr) 2019-04-30
MX2016003414A (es) 2016-06-30
PE20160527A1 (es) 2016-05-20
EP3046536A1 (en) 2016-07-27
PL3046536T3 (pl) 2019-06-28
SG11201601181SA (en) 2016-04-28
US20160199426A1 (en) 2016-07-14
JP2016530220A (ja) 2016-09-29

Similar Documents

Publication Publication Date Title
PH12016500316A1 (en) Improved adenovirus formulations
PL3349720T3 (pl) Biopochodna kompozycja emolientowa zawierająca izoparafiny
WO2013173789A3 (en) Antisense oligonucleotide compositions
IL252512A0 (en) Stable liquid formulations of vaccinia virus
JO3755B1 (ar) تركيبات تستوستيرون
EP2978423A4 (en) STABLE NANO COMPOSITION WITH DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
SI3261676T1 (sl) Formulacije tekočega levotiroksina
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
EP3319643A4 (en) HBED-BISPHOSPHONATES, CONJUGATES OF RADIOACTIVE METAL THEREOF, AND THEIR USE AS THERANOSTIC AGENTS
EP3369380A4 (en) COLLIMATOR FOR USE IN A SCANNING SYSTEM
EP2978428A4 (en) STABLE NANO COMPOSITION WITH EPIRUBICIN, PROCESS FOR THE PRODUCTION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
MX2015012905A (es) Formulaciones de factor viii recombinantes.
PL3360547T3 (pl) Bakteriobójcza kompozycja farmaceutyczna zawierająca ibuprofen
MY165088A (en) Pharmaceutical compositions comprising alisporivir
IL250913A0 (en) Platinum (iv) complexes, preparations containing them and their uses
MX2014015199A (es) Formulacion de pexiganan estable.
EP3132038A4 (en) Adenoviral targeting, compositions and methods therefor
RS65812B1 (sr) Čvrste kompozicije na bazi minerala i oralno razgradive formulacije koje ih sadrže
FR3003757B1 (fr) Compositions cosmetiques triphasiques comprenant des nacres
赵潇雨 Choose
UA90689U (uk) Комплексний протипаразитарний препарат "лактоверм"
TH1501000860A (th) สิ่งเตรียมทางเภสัชกรรมชนิดของแข็งที่มีลีไวไธโรซีน
TH1501004545A (th) องค์ประกอบทางเภสัชกรรมที่มีเด็กซ์คีโตโพรเฟนและทรามาดอล
TH1401007610A (th) องค์ประกอบที่ประกอบด้วยสารออกฤทธิ์ทางชีวภาพ

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.

FG Grant or registration